Clinical trials: Hypoxia
Persistent Pulmonary Hypertension of the Newborn, Hypoxic Respiratory Failure
Post Market Clinical Follow-up to Assess the Portable Nitric Oxide Generation and Delivery System (INOwill N200) for the Treatment of Neonatal Hypoxic Respiratory Failure Complicated by Pulmonary Hypertension
Title : A multicenter clinical trial of the portable nitric oxide generation and delivery system (INOwill N200) for the treatment of neonatal hypoxic respiratory failure complicated by pulmonary hypertension Investigational…
- Trial name
- iNOwill Neonat (NCT07837921)
- Testing
- Nitric Oxide Generator and Delivery System
- Volunteers
- 50 people
- Sponsor
- Novlead Inc.
Hypoxic-Ischemic Encephalopathy, Neonatal Asphyxia
Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
Sovateltide (PMZ-1620; IRL-1620) is targeted to be used as a "Treatment for hypoxic-ischemic encephalopathy in neonates," which is a life-threatening condition.
- Conditions
- Hypoxic-Ischemic Encephalopathy, Neonatal Asphyxia, Neonatal Encephalopathy
- Trial name
- NCT05514340
- Testing
- Normal Saline along with standard treatment, Sovateltide along with standard treatment
- Where
- 4 sites in India
- Volunteers
- 40 people
- Sponsor
- Pharmazz, Inc.
Hypoxia, Desaturation of Blood
SpO2 Accuracy Low Saturation Validation of the OxySoftN Sensor
To compare prototype pulse oximeter saturation measurements, during normal to low saturation, to saturation measurements made by a multi-wavelength CO-oximeter, taken from arterial blood samples from healthy human subjects.
- Trial name
- NCT04811963
- Testing
- Non-Invasive Controlled Hypoxia
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Intermittent Claudication, Peripheral Vascular Disease
Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication
The purpose of this Phase 2 clinical research study is to examine the safety of an experimental gene transfer agent, Ad2/HIF-1α/VP16, and its ability to stimulate the growth of new blood vessels from existing blood vessels (a…
- Conditions
- Intermittent Claudication, Peripheral Vascular Disease, Atherosclerosis
- Trial name
- WALK (NCT00117650)
- Testing
- Ad2/HIF-1α/VP16
- Where
- 47 sites in United States, Germany and 1 more
- Volunteers
- 289 people
- Sponsor
- Genzyme, a Sanofi Company
Flap Ischemia, Hypoxia
Spectroscopic Assessment of Tissue Oxygenation Changes in Plastic Surgical Flap Reconstructions
This study is a single-center, observational study designed to collect tissue spectrometric data.
- Trial name
- NCT07786610
- Volunteers
- 30 people
- Sponsor
- Spectrocor
Hypoxia, Ketosis
Ketone Esters for Optimization of Cognitive Performance in Hypoxia
This study will investigate the effects of ketone ester drinks on cognitive performance in hypoxia.
- Trial name
- NCT03659825
- Testing
- Ketone Ester, Hypoxic exposure
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- HVMN Inc
Non-small Cell Lung Cancer, NSCLC
Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients
This phase 2 study is designed to evaluate the safety and activity of TH-4000 a hypoxia-activated prodrug, in patients with EGFR-Mutant, T790M-Negative, Advanced NSCLC.
- Conditions
- Non-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC
- Trial name
- TH-4000 (NCT02454842)
- Testing
- TH-4000 (Tarloxotinib)
- Where
- 12 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Rain Oncology Inc
Healthy
The Accuracy of the Dormotech VLAB During Stable Hypoxia Plateaus
The purpose of the study is to determine the accuracy of the Dormotech VLAB (SpO2) Sensor in accordance with the FDA Guidance on Pulse Oximeters - Premarket Notification Submissions [510(k)s], in range of arterial HbO2…
- Trial name
- NCT06516809
- Testing
- DormoTech Vlab SpO2 sensor
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dormotech Medical
Hypoxia
Portable Oxygen Concentrator Signal Capture Study
The main purpose of this study is to learn how patients breathe on portable oxygen concentrators (POCs), and to get feedback from patients using POCs.
- Trial name
- NCT03182036
- Testing
- Portable pulsed oxygen
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- ResMed
Fetal Hypoxia, Fetal Acidemia
Dual System Study: Transvaginal Fetal Pulse Oximetry Measurement Systems
The objective of this study is to collect and compare fetal SpO2 waveforms and reference values to inform algorithm development for signal qualification and FSpO2 calculations. Subjects are women in labor.
- Trial name
- NCT07296419
- Testing
- Fetal Pulse Oximetery
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Raydiant Oximetry, Inc.
Lung Cancer, Squamous Cell Carcinoma
An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037
Phase: Exploratory Study Objectives: To collect drug bio-distribution data, begin collection of baseline and tumor/background imaging data, acquire experience to improve study design and the conduct of future studies Design…
- Conditions
- Lung Cancer, Squamous Cell Carcinoma, Head and Neck Cancer, Hepatic Carcinoma
- Trial name
- VM4-037 (NCT00884520)
- Testing
- [F-18] VM4-037
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Siemens Molecular Imaging
Carcinoma, Lymphoma
Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma
This is a Phase 1, open-label, non-randomized, dose-escalation study to determine the maximum tolerated dose (MTD), safety, tolerance, and pharmacologic profile of EZN-2968, a locked nucleic acid antisense oligonucleotide against…
- Trial name
- NCT00466583
- Testing
- Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Tumors, Hypoxia
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
This is a phase I, multi-center, open-label, dose-escalation study of TH-302 in patients with advanced solid tumors. TH-302 is a hypoxia activated product designed to exploit the hypoxic nature of tumors.
- Trial name
- NCT00495144
- Testing
- TH-302
- Where
- 7 sites in United States
- Volunteers
- 129 people
- Sponsor
- Threshold Pharmaceuticals
Nocturnal Hypoxemia
Evaluation of POC Pulse-dose Demand Oxygen Delivery for Nocturnal Hypoxemia
The aim of this study is to describe the effect of the Inogen Rove 6 Portable Oxygen Concentrator on peripheral oxygen saturation in adults receiving supplemental oxygen at night and examine whether the device can adequately…
- Trial name
- NCT06000332
- Testing
- InogenOne Rove 6 Portable Oxygen Concentrator
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Inogen Inc.
Hypoxia
Polso SpO2 Accuracy Validation Study
The purpose of this study is to validate the oxygen saturation (SpO2) accuracy of the Polso Monitoring System during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by…
- Trial name
- NCT03735329
- Testing
- Diagnostic test of SPO2
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- ChroniSense Medical Ltd.
Epilepsy, Dravet Syndrome
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
The purpose of this study is to investigate the effect on the frequency of all seizures (convulsive and drop) in participants treated with TAK-935 compared to placebo.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Trial name
- ELEKTRA (NCT03650452)
- Testing
- TAK-935
- Where
- 44 sites in United States, Australia and 6 more
- Volunteers
- 141 people
- Sponsor
- Takeda
Acute Respiratory Distress Syndrome (ARDS), Pneumonia
Medical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning.
Pre-market clinical trial on 81 aldults participants to evidence safety and performance of the non-CE-marked medical device INBENTUS VERSATILE ventilator.
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), Pneumonia, COPD (Chronic Obstructive Pulmonary Disease), Postoperative Respiratory Distress
- Trial name
- NCT07432191
- Testing
- INBENTUS VERSATILE
- Where
- Spain
- Volunteers
- 81 people
- Sponsor
- Iconic Solutions By Murcia SL
COPD
Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.
- Trial name
- NCT07222410
- Testing
- Closed loop oxygen control, Manual titration
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Fisher and Paykel Healthcare
Severe Hypoxic Ischemic Encephalopathy, Moderate Hypoxic Ischemic Encephalopathy
Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy
The purpose of this study is to assess whether the addition of a drug such as Magnesium sulphate while providing therapeutic hypothermia (or cooling) to babies who are asphyxiated at birth provides additional benefit to the…
- Trial name
- MagCool (NCT01646619)
- Testing
- Magnesium Sulphate
- Where
- 7 sites in Egypt, Malaysia and 4 more
- Volunteers
- 300 people
- Sponsor
- Sajjad Rahman
Carcinoma, Hepatocellular
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
This open-label study will demonstrate proof-of-mechanism of HIF1A inhibition by a decrease of HIF1A mRNA after intravenous (IV) infusion of RO7070179 in participants with hepatocellular carcinoma (HCC) who have failed at least…
- Trial name
- NCT02564614
- Testing
- RO7070179
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Hoffmann-La Roche